Document is current
Any future updates will be listed below
-
Authors
Petersen, Jakob
Malyutina, Sofia
Ryabikov, Andrey
Kontsevaya, Anna
Kudryavtsev, Alexander V.
Eggen, Anne Elise
McKee, Martin
Cook, Sarah
Hopstock, Laila A.
Schirmer, Henrik
Leon, David A.
-
Funding
Funding for this research was provided by:
Wellcome Trust (1000217)
- License Information
-
More Information
Article History
Received: 13 November 2019
Accepted: 28 February 2020
First Online: 13 March 2020
Ethics approval and consent to participate
: Ethical approval for KYH was received from the ethics committees of the London School of Hygiene & Tropical Medicine (approval number 8808), Novosibirsk State Medical University (approval number 75; 21 May 2015), the Institute of Preventative Medicine (approval received 26 December 2014), Novosibirsk and the Northern State Medical University, Arkhangelsk (approval number 01/01–15; 27 January 2015). Tromsø 7 obtained ethical approval from Regional Committee of Medical and Health Research Ethics (REC North) (approval number 2014/940) and Norwegian Data Protection Authority, and was conducted in accordance with the 1964 Helsinki Declaration and its later amendments. Participants gave written informed consent.
: Not applicable.
: HS have received lecture fees from pharmaceutical companies with market authorisation for antihypertensives (Novartis, MSD, Astra Zeneca, Sanofi Aventis). Other authors have no competing interests to declare (SM, AR, AKo, AKu, AEE, MM, SC, LAH, DL, JP).
